On November 4, 2026 Sumitomo Pharma America, Inc. (SMPA) reported two oral presentations and two poster presentations at the 68th American Society of Hematology (ASH) (Free ASH Whitepaper) Annual Meeting & Exposition, taking place December 12-15, 2026, in New Orleans, Louisiana. The presentations will feature new clinical data on enzomenib, an investigational oral small molecule menin inhibitor being studied in genetic subtypes of relapsed or refractory (R/R) acute leukemia (AL), and nuvisertib, an investigational oral small molecule highly selective PIM1 kinase inhibitor with added ACVR1 inhibition being evaluated in combination with momelotinib (MMB) in patients with R/R myelofibrosis (MF).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"There remains a high unmet medical need for patients with R/R acute myeloid leukemia with KMT2Ar or NPM1m for targeted therapies that yield robust response rates and durable response that are well tolerated," said Jatin Shah, M.D., Chief Medical Officer, Oncology, SMPA. "In addition, new classes of therapeutics and combination strategies to potentially improve upon the activity of JAK inhibitors are important in MF. With this in mind, we look forward to sharing encouraging new data that further support the therapeutic potential and development of our late-stage oncology pipeline at ASH (Free ASH Whitepaper)."

For enzomenib, the oral presentation will report efficacy and safety data from the pivotal Phase 2 arm of the Horizen-1 study in patients with R/R KMT2A rearrangements (KMT2Ar) AL. The data will highlight the therapeutic potential of enzomenib as a targeted treatment option for patients with this high-risk subset of AL.

Additionally, a poster presentation will include clinical findings from the completed dose optimization study of enzomenib that informed the recommended Phase 2 dose (RP2D) in patients with R/R AL with NPM1 mutation (NPM1m). The data demonstrated that both 200 mg twice a day (BID) and 300 mg BID of enzomenib were generally well tolerated with measurable clinical activity. Objective response rates (ORRs) were 54% and 57% in patients receiving 200 and 300 mg BID, respectively, while the complete remission and complete remission with partial hematologic recovery (CR+CRh) rates were 35% at 200 mg BID and 43% at 300 mg BID.

For nuvisertib, the oral presentation will report preliminary findings from the ongoing global Phase 1 dose escalation study evaluating nuvisertib and MMB in patients with MF previously treated with a JAK inhibitor show the combination appeared to be well tolerated in the dose levels evaluated. Promising clinical activity included symptom and spleen responses, anemia improvement, and cytokine modulation. These emerging clinical data support the Phase 3 clinical development of nuvisertib in combination with MMB for patients with MF and anemia.

Presentation Details

Title

Details

Presenting Author

Investigational PIM1 kinase inhibitor nuvisertib in combination with momelotinib showed promising clinical activity in patients with myelofibrosis and anemia: Preliminary data from an ongoing Phase 1/2 study

Oral Presentation

Session: 634. Myeloproliferative Syndromes: Clinical and Epidemiological: Combining Forces Against Myelofibrosis

Sunday, December 13, 2026

9:30—11 a.m. CST

Presentation Time: 9:45—10 a.m. CST

Room: R02-R05 (New Orleans Ernest N. Morial Convention Center)

Lindsay A.M. Rein, M.D.

Selective PIM1 inhibition with nuvisertib promotes megakaryocyte maturation and platelet production in myelofibrosis patients

Poster Presentation

Session: 631. Myeloproliferative Syndromes and Chronic Myeloid Leukemia: Basic and Translational: Poster I

Saturday, December 12, 2026

5:30—7:30 p.m. CST

Room: Hall F (New Orleans Ernest N. Morial Convention Center)

Lilian Varricchio, Ph.D.

Initial report of the Phase 2 pivotal data in patients with relapsed or refractory KMT2Ar acute leukemia from the phase 1/2 trial of the investigational menin inhibitor enzomenib (DSP-5336)

Oral Presentation

Session: 616. Acute Myeloid Leukemias: Investigational Drug and Cellular Therapies – Novel Combinations with Menin, FLT3 and BCL2 Inhibitors

Sunday, December 13, 2026

4:30—6 p.m. CST

Presentation Time: 5—5:15 p.m. CST

Room: Hall B (New Orleans Ernest N. Morial Convention Center)

Harry P. Erba, M.D., Ph.D.

Enzomenib dose optimization and determination of the recommended Phase 2 dose in patients (pts) with relapsed or refractory NPM1m acute leukemia

Poster Presentation

Session: 616. Acute Myeloid Leukemias: Investigational Drug and Cellular Therapies: Poster III

Monday, December 14, 2026

6—8 p.m. CST

Presentation Time: 6—8 p.m. CST

Room: Hall F (New Orleans Ernest N. Morial Convention Center)

Cristina Papayannidis, M.D., Ph.D.

About Enzomenib (DSP-5336)
Enzomenib is an investigational, oral, small molecule inhibitor of the menin and lysine (K)-specific methyltransferase 2A (KMT2A) protein interaction, a key interaction in acute leukemia and other tumor cell proliferation and growth.1 Menin is a scaffold nuclear protein that plays key roles in gene expression and protein interactions involved in many biological pathways, including cell growth, cell cycle, genomic stability, and hematopoiesis.2,3 In preclinical studies, enzomenib has shown selective growth inhibition in human acute leukemia cell lines with KMT2A rearrangements or NPM1 mutations.4 Enzomenib reduced the expression of the leukemia-associated genes HOXA9 and MEIS1 and increased the expression of the differentiation gene CD11b in human acute leukemia cell lines with KMT2A rearrangements or NPM1 mutations.1,4 The safety and efficacy of enzomenib are currently being clinically evaluated in a Phase 1/2 dose-escalation/dose-expansion study in patients with relapsed or refractory acute leukemia (NCT04988555) and the registrational Phase 2 Horizen-1 R/R mono AML/ALL (KMT2Ar + NPM1m) study. The FDA granted Orphan Drug Designation for enzomenib for the indication of acute myeloid leukemia in June 2022 and the indication of acute lymphoblastic leukemia in July 2026. The FDA granted Fast Track Designation for enzomenib for the indication of relapsed or refractory acute myeloid leukemia with KMT2Ar or NPM1m in June 2024 and Breakthrough Therapy Designation for the treatment of patients with relapsed/refractory acute leukemia with KMT2Ar in October 2026. Japan’s Ministry of Health, Labour and Welfare (MHLW) granted Orphan Drug Designation for enzomenib for the indication of relapsed or refractory acute myeloid leukemia with KMT2Ar or NPM1m in September 2024.

About Nuvisertib (TP-3654)
Nuvisertib is an oral investigational selective inhibitor of PIM1 kinase with added ACVR1 inhibition, which has shown potential antitumor and antifibrotic activity through multiple pathways, including induction of apoptosis in preclinical models.5-7 Nuvisertib was observed to inhibit proliferation and increase apoptosis in murine and human hematopoietic cells expressing the clinically relevant JAK2 V617F mutation.6 Nuvisertib alone and in combination with ruxolitinib showed reduction of spleen size and bone marrow fibrosis in JAK2 V617F and MPLW515L murine models of myelofibrosis.6 In addition to its primary activity against PIM1, nuvisertib has been shown to bind and inhibit ACVR1 in preclinical studies, which may contribute to hemoglobin responses in patients with myelofibrosis.7 The safety and efficacy of nuvisertib monotherapy or in combination with a JAK inhibitor are currently being clinically evaluated in a Phase 1/2 study in patients with intermediate- and high-risk myelofibrosis (NCT04176198). The FDA granted Orphan Drug Designation to nuvisertib for the indication of myelofibrosis in May 2022. The Japan Ministry of Health, Labour and Welfare (MHLW) granted Orphan Drug Designation to nuvisertib for the treatment of myelofibrosis in November 2024. The European Medicines Agency (EMA) granted Orphan Drug Designation to nuvisertib for the treatment of myelofibrosis in July 2025. The FDA granted Fast Track Designation to nuvisertib for the indication of myelofibrosis in June 2025.

(Press release, Sumitomo Dainippon Pharma, NOV 4, 2026, View Source [SID1234674203])

On November 4, 2026 Elicio Therapeutics, Inc. (Nasdaq: ELTX) ("Elicio" or the "Company"), a clinical-stage biotechnology company developing next-generation immunotherapies for KRAS-driven cancers, reported that it will host a virtual key opinion leader ("KOL") event on Wednesday, November 11, 2026, at 2:30 PM ET. To register, click here.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The event will feature expert oncologists Eileen M. O’Reilly, MD, FASCO and Kevin C. Soares, MD, both of Memorial Sloan Kettering Cancer Center ("MSKCC"), who will join the Company’s management to discuss:

The unmet need and current treatment landscape for metastatic pancreatic ductal adenocarcinoma ("PDAC")
Camupepimut (ELI-002 7P), Elicio’s investigational Amphiphile ("AMP")-powered immunotherapy targeting common KRAS mutations
Key Phase 2 findings informing camupepimut’s late-stage development strategy
Opportunities to expand camupepimut into neoadjuvant PDAC, including the design and progress of the ongoing MSKCC-led Phase 1 trial funded by The Lustgarten Foundation and Break Through Cancer
A live question and answer session will follow the formal presentations.

About Eileen M. O’Reilly, MD, FASCO
Eileen M. O’Reilly holds the Winthrop Rockefeller Endowed Chair in Medical Oncology at MSKCC. She serves as the Section Head for Hepatopancreaticobiliary/Neuroendocrine Cancers, Gastrointestinal Oncology Service, Co-Director Medical at the David M. Rubenstein Center for Pancreatic Cancer and is an Attending Physician and Member at MSKCC and Professor of Medicine at Weill Cornell Medical College.

Dr. O’Reilly is a clinical scientist whose research focus involves integration of molecular, genetic-based (RAS, BRCA, other) and immunotherapy for pancreas cancer along with development of adjuvant and neoadjuvant treatments and identification of biomarkers for therapy selection. Dr. O’Reilly teaches and mentors junior faculty, oncology fellows, residents and medical/other students. Dr. O’Reilly is the Principal Investigator of multiple phase I, II, III trials in pancreas cancer. She is a Clarivate highly cited author in clinical medicine. She serves as an Associate Editor for the Journal of Clinical Oncology and Senior Editor for several AACR (Free AACR Whitepaper) journals and has served on multiple grant review panels including, for the American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) ("ASCO"), American Association forCancer Research ("AACR"), National Institutes of Health ("NIH"), Department of Defense ("DOD"), and various international entities. She is Principal Investigator of the MSK P50 Pancreas Specialized Program of Research Excellence ("SPORE"), a National Cancer Institute ("NCI") funded team science grant. Dr. O’Reilly is the recipient of named lectureships and numerous awards including the Burkitt Medal (Trinity College Dublin) in 2022, Giants of Cancer Care (GI Oncology) in 2023 and the Whitman Award for Clinical Excellence in 2025, Exceptional Women in Medicine (2019- present) and Castle Connolly Top Doctors (2005- present).

Dr. O’Reilly’s other roles include Chair of the Human Research Protection Program and Institutional Review & Privacy Board ("IRB"). Nationally, Dr. O’Reilly is Co-Chair of the NCI Alliance Co-Operative Group Gastrointestinal Cancers Committee and serves in leadership roles in several advocacy organizations including the National Pancreas Foundation, Hirshberg Foundation, PanKind and Pancreatic Cancer Action Network.

About Kevin C. Soares, MD
Dr. Kevin C. Soares obtained his undergraduate degree at Brandeis University and MD from the University of Massachusetts Medical School. He completed general surgery residency at The Johns Hopkins University School of Medicine. He completed a three-year research fellowship in cancer immunology in the Jaffee Laboratory at the Sidney Kimmel Comprehensive Cancer Center atThe Johns Hopkins University School of Medicine. After finishing residency, he completed a two-year dual fellowship in complex surgical oncology and hepatopancreatobiliary ("HPB") surgery at MSKCC. He was then appointed to the faculty of the HPB Service at MSKCC and completed a Master of Science in clinical and translational cancer research at the Louis V. Gerstner Jr. Graduate School of Biomedical Sciences,MSKCC.

Dr. Soares is a surgical oncologist and physician scientist who specializes in caring for patients with HPB malignancies. His primary research interest is combinatorial immunotherapy approaches in HPB malignancies with a particular focus on vaccine-based therapies.

About the AMPLIFY-7P Phase 2 Study

AMPLIFY-7P is a randomized Phase 2 study evaluating camupepimut (ELI-002 7P) versus observation in patients with mKRAS-driven PDAC following completion of standard therapy. The study enrolled 144 patients across 24 U.S. clinical sites.

While the study did not meet its pre-specified primary disease-free survival ("DFS") endpoint in the intent-to-treat population, subsequent analyses have provided important insights into the clinical and biological activity of camupepimut and informed the Company’s continued evaluation of the program.

At ESMO (Free ESMO Whitepaper) Congress 2026, Elicio will present new pre-specified analyses from AMPLIFY-7P that provide additional insights into the potential clinical benefit ofcamupepimut and are expected to further inform the Company’s refined Phase 3 development strategy in adjuvant pancreatic cancer.

About camupepimut (ELI-002 7P)

Camupepimut is an investigational, off-the-shelf immunotherapy designed to generate immune responses against seven of the most common KRAS mutations. Camupepimut utilizes Elicio’s proprietary AMP technology to target mutant KRAS peptide antigens and an immune-stimulatory adjuvant directly to the lymph nodes, where adaptive immune responses are orchestrated.

(Press release, Elicio Therapeutics, NOV 4, 2026, View Source [SID1234674202])

On November 4, 2026 Immuneering Corporation (Nasdaq: IMRX), a late-stage clinical oncology company focused on keeping cancer patients alive and helping them thrive, reported that two abstracts evaluating atebimetinib (IMM-1-104), its lead investigational candidate designed to provide Deep Cyclic Inhibition of the MAPK pathway, have been accepted for presentation at the 2026 EORTC-NCI-AACR (Free EORTC-NCI-AACR Whitepaper) Symposium on Molecular Targets and Cancer Therapeutics, taking place November 17–19, 2026.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The presentations will highlight new preclinical findings supporting the potential of atebimetinib in combination with multiple targeted therapies in pancreatic ductal adenocarcinoma (PDAC), as well as chemotherapy combinations in anaplastic thyroid cancer (ATC). The pancreatic cancer abstract has been selected for a Poster Spotlight presentation.

Presentation Details:

Pancreatic Ductal Adenocarcinoma – Poster Spotlight Presentation
Title: Patient-aligned 3D tumor models identify biomarker-enriched atebimetinib (IMM-1-104) combination strategies in pancreatic ductal adenocarcinoma
Abstract Number: 22
Poster Number: PB-003
Presenter: Anna Travesa, Immuneering Corporation
Date: November 19, 2026
Time: 14:00–14:30 CET
Session: Poster Spotlight Session

Anaplastic Thyroid Cancer – Preclinical Poster Presentation
Title: Atebimetinib, a deep cyclic inhibitor of MEK, combined with chemotherapy: preclinical rationale for treatment of anaplastic thyroid cancer (ATC)
Abstract Number: 144
Poster Number: PB-144
Presenter: Praveen Nair, Immuneering Corporation
Date: November 18, 2026
Session: Translational Studies

Following presentation, the poster will be available on the publications section of Immuneering’s website at View Source

(Press release, Immuneering, NOV 4, 2026, View Source [SID1234674201])

On November 4, 2026 Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, reported that preliminary clinical data from the Phase 1 study of ARV-393 (zaloblideg) in patients with relapsed/refractory non-Hodgkin lymphoma (NHL) will be presented at the 2026 American Society of Hematology (ASH) (Free ASH Whitepaper) Annual Meeting, taking place December 12- 15, 2026, in New Orleans, Louisiana.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

ARV-393 (zaloblideg) is Arvinas’ investigational, orally bioavailable PROteolysis TArgeting Chimera (PROTAC) designed to specifically target and degrade the B-cell lymphoma 6 (BCL6) protein. BCL6 is a master regulator of germinal center B-cell development, an established oncogenic driver in multiple NHLs and more recently implicated in nodal T-follicular helper cell lymphoma of angioimmunoblastic type (nTFHL-AI, formerly AITL).

The presentation details are as follows:

Presentation Title: ARV-393, an oral PROTAC BCL6 degrader, in patients with non-Hodgkin lymphoma: Preliminary results from a phase 1 study
Presentation Type: Poster
Session Number: 627
Session Title: Aggressive Lymphomas: Targeted and Pharmacologic Therapies: Poster III
Session Location: MCCNO – Hall F
Publication Number: 5409
Date: Monday, December 14
Session Time: 6:00-8:00 PM CT

The full abstract can be accessed via the ASH (Free ASH Whitepaper) online program.

About ARV-393 (zaloblideg)
Zaloblideg is an investigational, orally bioavailable PROTAC designed to specifically target and degrade B-cell lymphoma 6 protein (BCL6), a transcriptional repressor and major driver of B-cell lymphomas. During B-cell development, tightly controlled BCL6 protein expression regulates >600 genes to facilitate rapid B-cell proliferation and tolerance of somatic hypermutation and gene recombination for antibody generation. Deregulated BCL6 expression is common in B-cell lymphoma and promotes cancer cell survival, proliferation, and genomic instability. PROTAC-mediated degradation has the potential to address the historically undruggable nature of BCL6. ARV-393 (zaloblideg) is currently being evaluated in a Phase 1 clinical trial as a monotherapy in patients with relapsed/refractory non-Hodgkin lymphoma and in in combination with glofitamab as a chemotherapy-free combination approach in patients with DLBCL.

(Press release, Arvinas, NOV 4, 2026, View Source [SID1234674200])

On November 4, 2026 Lyell Immunopharma, Inc. (Nasdaq: LYEL), a late-stage clinical company advancing a pipeline of next-generation chimeric antigen receptor (CAR) T-cell therapies for patients with cancer, reported financial results and business highlights for the third quarter ended September 30, 2026.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"The updated ronde-cel data accepted for presentation at ASH (Free ASH Whitepaper) further strengthen our conviction in ronde-cel’s potential to meaningfully improve outcomes for patients with large B-cell lymphoma," said Lynn Seely, M.D., President and Chief Executive Officer of Lyell. "The high rates of very durable complete responses achieved by ronde-cel in both the second- and third- or later-line settings, including in patients with high-risk primary refractory disease, clearly showcase the next-generation potential of ronde-cel. With two pivotal trials underway, including our single-arm pivotal PiNACLE trial expected to complete enrollment by year end and on track for pivotal data and BLA submission in the second half of 2027, we are now focusing on preparation for commercialization. We are also continuing to advance LYL273 following the successful transfer of manufacturing to LyFE, as we work to determine the recommended Phase 2 dose and optimize the safety management plan ahead of our planned End-of-Phase 1 discussions with the FDA in 2027."

Third Quarter Updates and Recent Business Highlights

Rondecabtagene Autoleucel (ronde-cel): A next-generation dual-targeting CD19/CD20 CAR T-cell product candidate designed to increase complete response rates and prolong the duration of response as compared to approved CD19‑targeted CAR T-cell therapies for the treatment of relapsed/refractory large B-cell lymphoma

Ronde-cel is an autologous CAR T-cell product candidate under evaluation in two pivotal trials in patients with relapsed/refractory (R/R) large B-cell lymphoma (LBCL) in the third- or later-line (3L+) setting (PiNACLE) and the second-line (2L) setting (PiNACLE‑H2H). A multi-cohort dose-escalation, dose-expansion Phase 1/2 trial is also ongoing. Ronde-cel targets B cells that express either CD19 or CD20 with a true ‘OR’ logic gate to achieve full potency at either target and is manufactured with a process that enriches for CD62L-positive cells to generate more naïve and central memory CAR T cells with enhanced stemlike features and antitumor activity. The U.S. Food and Drug Administration (FDA) has granted ronde-cel Regenerative Medicine Advanced Therapy (RMAT) and Fast Track designations for the treatment of adults with R/R diffuse LBCL in the 3L+ setting and also RMAT designation for the treatment of LBCL in the 2L setting.

Lyell announced today updated clinical data from the ongoing PiNACLE pivotal trial in patients with 3L+ R/R LBCL and from the Phase 1/2 trial 2L cohort of ronde-cel in patients with R/R LBCL in two abstracts accepted for presentation at the 68th American Society of Hematology (ASH) (Free ASH Whitepaper) Meeting and Exposition (ASH 2026), taking place December 12–15, 2026.
The PiNACLE pivotal single-arm trial, a seamless expansion of the 3L+ cohort in the Phase 1/2 multi-cohort trial, is ongoing. Pivotal data are expected in mid-2027 with submission of a Biologics License Application (BLA) to the FDA expected to follow in the second half of 2027. The primary endpoint of the trial is overall response rate, including an evaluation of duration of response.
PiNACLE-H2H, the first-of-its-kind Phase 3 randomized controlled trial evaluating ronde-cel versus investigator’s choice of axicabtagene ciloleucel or lisocabtagene maraleucel in patients with R/R LBCL in the 2L setting, continues to enroll patients. The trial’s primary endpoint is event-free survival.
LYL273: A next-generation guanylyl cyclase C (GCC)-targeted CAR T-cell product candidate for the treatment of relapsed/refractory metastatic colorectal cancer (mCRC) and other GCC-expressing cancers

LYL273 is a GCC-targeted CAR T-cell product candidate enhanced with CD19 CAR expression and controlled cytokine release, designed to improve CAR T-cell expansion, immune cell infiltration and cancer cell killing in the hostile solid tumor microenvironment. The FDA granted LYL273 Fast Track designation for the treatment of mCRC.

In September 2026, Lyell completed the planned technology transfer for LYL273 to its LyFE Manufacturing Center (LyFE) in Bothell, Washington, following FDA review of an improved manufacturing process and updated analytical methods. LyFE is implementing the improved manufacturing process and updated analytical methods to enhance manufacturing performance and increase capacity. The Phase 1/2 clinical trial of LYL273 in patients with R/R mCRC continues to enroll patients, including dosing of patients with LYL273 manufactured using the new process at LyFE, with the goal of determining the recommended Phase 2 dose and optimizing the safety management plan.
Additional clinical data from the Phase 1/2 trial of LYL273 in patients with 3L+ R/R mCRC and an End-of-Phase 1 meeting with the FDA are expected in 2027.
Corporate Update

In November 2026, the Company announced a private placement of $80.0 million with participation from a high-quality syndicate of existing and new investors. The proceeds are expected to extend cash runway into 2028, beyond anticipated BLA submission for ronde-cel in the second half of 2027, as well as updated clinical data from the GCC-targeted LYL273 program for patients with mCRC.
Third Quarter 2026 Financial Results

Lyell reported a net loss of $45.5 million for the third quarter ended September 30, 2026, compared to a net loss of $38.8 million for the same period in 2025. The $6.7 million increase in net loss was primarily due to a $12.7 million increase in research and development expenses driven by increased clinical trial activity, partially offset by a $4.0 million prior-year loss on the securities purchase agreement put/call that did not recur. Non‑GAAP net loss, which excludes non-cash stock-based compensation, non-cash expenses related to the change in the estimated fair value of the securities purchase agreement put/call relating to the Company’s July 2025 private placement transaction and success payment liabilities, increased by $12.2 million to $41.3 million for the third quarter ended September 30, 2026, compared to $29.1 million for the same period in 2025, primarily due to increased clinical trial activity and lower interest income.

GAAP and Non-GAAP Operating Expenses

Research and development (R&D) expenses were $40.9 million for the third quarter ended September 30, 2026, compared to $28.2 million for the same period in 2025. The $12.7 million increase was primarily due to a $12.2 million increase in research activities, collaborations and outside services due to increased clinical trial activity. Non‑GAAP R&D expenses, which exclude non-cash stock-based compensation, for the third quarter ended September 30, 2026 were $38.8 million compared to $26.2 million for the same period in 2025.
General and administrative (G&A) expenses were $9.3 million for the third quarter ended September 30, 2026, compared to $10.7 million for the same period in 2025, primarily due to lower professional services expenses. Non‑GAAP G&A expenses, which exclude non-cash stock‑based compensation, for the third quarter ended September 30, 2026 were $6.9 million compared to $7.5 million for the same period in 2025.
A discussion of non-GAAP financial measures, including reconciliations of the most comparable U.S. generally accepted accounting principles (GAAP) measures to non‑GAAP financial measures, is presented below under "Non-GAAP Financial Measures."

Cash, cash equivalents and marketable securities

Cash, cash equivalents and marketable securities as of September 30, 2026 were $194.0 million compared to $247.2 million as of December 31, 2025. Lyell believes that its current cash, cash equivalents and marketable securities balances, together with the net proceeds from the $80.0 million private placement in November 2026, will be sufficient to meet working capital and capital expenditure needs into 2028.

(Press release, Lyell Immunopharma, NOV 4, 2026, View Source [SID1234674199])